rates of response of the NIH-CPSI in the alfuzosin group and placebo groups were the same 49.4 percent. In addition, there were no significant differences between the two groups in the changes over time in most of the secondary outcomes, including the total NIH-CPSI score and a global response assessment.
Despite a lack of rigorous evidence supporting the use of antibiotics or alpha blockers for chronic prostatitis, more than three-fourths of primary care physicians often prescribe antibiotics and more than one-half regularly prescribe alpha blockers such as alfuzosin for the condition, according to a recent survey supported by NIDDK. Alpha blockers are a class of drugs that relax the smooth muscle of the bladder and prostate.
"Our findings do not support the use of alpha blockers for treating new cases of chronic prostatitis," said J. Curtis Nickel, M.D., of Queen's University in Kingston, Ontario, Canada, and lead author of the study. "But the results of our study will inform future clinical trials of alpha blockers and other potential therapies."
'/>"/>
Page: 1 2 Related medicine news :1.
UK junior doctors gaining less experience of common procedures2.
New insights into common knee injuries3.
High and mighty: first common height gene identified by researchers behind obesity gene finding4.
Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint5.
Exelixis Commences Public Offering of Common Stock6.
Common misdiagnosis: most women believe they have a yeast infection when they dont7.
Business Executives Discuss National Health Care Reform at Conference Sponsored by The Century Foundation, with Support from The Commonwealth Fund, and AARP8.
New Expert Report Dispels Common Myths About Aspartame9.
Common Foot Myths Trip Us Up10.
AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange11.
Allergy-Induced Asthma More Common in Affluent Countries